Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MRK NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$84.11-0.7%$83.76$73.31▼$111.20$211.56B0.3713.87 million shs9.17 million shsTRVITrevi Therapeutics$10.62+4.2%$8.32$2.36▼$10.86$1.24B0.741.93 million shs2.18 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.-0.84%-2.64%+3.74%+3.09%-24.60%TRVITrevi Therapeutics+4.22%+8.15%+31.76%+55.26%+233.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$84.11-0.7%$83.76$73.31▼$111.20$211.56B0.3713.87 million shs9.17 million shsTRVITrevi Therapeutics$10.62+4.2%$8.32$2.36▼$10.86$1.24B0.741.93 million shs2.18 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.-0.84%-2.64%+3.74%+3.09%-24.60%TRVITrevi Therapeutics+4.22%+8.15%+31.76%+55.26%+233.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRKMerck & Co., Inc. 2.29Hold$105.0024.84% UpsideTRVITrevi Therapeutics 2.89Moderate Buy$21.75104.80% UpsideCurrent Analyst Ratings BreakdownLatest MRK and TRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025MRKMerck & Co., Inc.CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$84.00 ➝ $95.0010/8/2025MRKMerck & Co., Inc.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025TRVITrevi TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MRKMerck & Co., Inc.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025TRVITrevi TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/17/2025MRKMerck & Co., Inc.Berenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$100.00 ➝ $90.008/21/2025TRVITrevi TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$18.008/8/2025TRVITrevi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$29.00 ➝ $27.008/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $22.007/30/2025MRKMerck & Co., Inc.Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$97.00 ➝ $90.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRKMerck & Co., Inc.$63.62B3.30$9.40 per share8.95$18.33 per share4.59TRVITrevi TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRKMerck & Co., Inc.$17.12B$6.4912.968.500.9325.79%41.05%16.55%10/30/2025 (Estimated)TRVITrevi Therapeutics-$47.91M-$0.42N/AN/AN/AN/A-41.44%-38.21%11/5/2025 (Estimated)Latest MRK and TRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025TRVITrevi Therapeutics-$0.10N/AN/AN/AN/AN/A10/30/2025Q3 2025MRKMerck & Co., Inc.$2.37N/AN/AN/A$17.00 billionN/A8/7/2025Q2 2025TRVITrevi Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A7/29/2025Q2 2025MRKMerck & Co., Inc.$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRKMerck & Co., Inc.$3.243.85%N/A49.92%14 YearsTRVITrevi TherapeuticsN/AN/AN/AN/AN/ALatest MRK and TRVI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/22/2025MRKMerck & Co., Inc.quarterly$0.814%9/15/20259/15/202510/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRKMerck & Co., Inc.0.691.421.17TRVITrevi TherapeuticsN/A22.4222.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRKMerck & Co., Inc.76.07%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipMRKMerck & Co., Inc.0.13%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRKMerck & Co., Inc.75,0002.50 billion2.49 billionOptionableTRVITrevi Therapeutics20121.78 million99.49 millionOptionableMRK and TRVI HeadlinesRecent News About These CompaniesTrevi Therapeutics (NASDAQ:TRVI) Reaches New 52-Week High - Here's WhyOctober 14 at 2:07 PM | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Down - Time to Sell?October 13 at 11:56 AM | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Earns "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comBrokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $21.75October 9, 2025 | americanbankingnews.comTrevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual MeetingOctober 8, 2025 | prnewswire.comCantor Fitzgerald Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)October 7, 2025 | theglobeandmail.comTrevi Therapeutics (TRVI) Receives a Buy from Leerink PartnersOctober 7, 2025 | theglobeandmail.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Moderate Buy" from AnalystsOctober 4, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month High - Here's What HappenedOctober 3, 2025 | marketbeat.comTrevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific DebutSeptember 23, 2025 | finance.yahoo.comHow Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025September 20, 2025 | finance.yahoo.comTrevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025September 18, 2025 | prnewswire.comHaduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan StanleySeptember 11, 2025 | msn.comTrevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comTrevi spikes as B. Riley reportedly cites deal prospectsAugust 28, 2025 | msn.comTrevi Therapeutics to Participate in Upcoming September ConferencesAugust 28, 2025 | prnewswire.comMorgan Stanley Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight RecommendationAugust 22, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), DENTSPLY SIRONA (XRAY) and Arrowhead Pharmaceuticals (ARWR)August 13, 2025 | theglobeandmail.comTrevi Therapeutics: Optimism Amid Earnings Call InsightsAugust 13, 2025 | msn.comTrevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth PlansAugust 10, 2025 | finance.yahoo.comTrevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRK and TRVI Company DescriptionsMerck & Co., Inc. NYSE:MRK$84.11 -0.59 (-0.70%) Closing price 10/15/2025 03:59 PM EasternExtended Trading$84.40 +0.29 (+0.35%) As of 08:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Trevi Therapeutics NASDAQ:TRVI$10.62 +0.43 (+4.22%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$10.60 -0.01 (-0.14%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
